ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS

摘要:

AimThe overall aim of the REassessment of Antihypertensive Chronic Therapy (REACT) study was to perform a comprehensive assessment of the management of hypertensive patients in Italy from both the physician and patient point of view. This included an evaluation of prescribing practices, global risk factor stratification, an assessment of physician/patient satisfaction with the ongoing therapeutic regimen and an evaluation of quality of life.Experimental designREACT was a multicentre, noninterventional, cross-sectional, observational study of the management of hypertension in Italy. Patients were selected from hypertension clinics, and several specialties are represented, including cardiology, internal medicine, geriatrics, diabetology and nephrology.Patient populationBetween 10 and 20 patients were enrolled in each of the 131 participating centres. Eligible patients were required to have been diagnosed with primary hypertension for at least 1 year and to have been receiving stable antihypertensive therapy for at least 1 year.Study durationEnrolment began in March 2003 and concluded in March 2004. The final study results are expected in September 2004.EndpointA complete evaluation of physician and patient satisfaction with antihypertensive therapy by comprehensively reassessing various parameters such as blood pressure levels, target organ damage, tolerability and quality of life.

ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS

摘要:

The renin-angiotensin-aldosterone system (RAAS) is considered to be the main mediator of the cardiovascular damage associated with high blood pressure. Recent guidelines recognised, both directly and indirectly, the central role of RAAS, reporting the ‘compelling indications’ for the use of drugs that antagonise this system. The results of many large trials with the angiotensin receptor blockers (ARBs) candesartan, losartan, irbesartan and valsartan have been published from the year 2000 to the end of 2003. These trials have been conducted to verify that, beyond blood pressure control, ARBs could offer better organ protection in many different clinical conditions. Despite the favourable premises, some ARB trials not only failed to show superiority, but even equivalence with lower-cost therapies of confirmed efficacy (e.g. captopril 50mg three times daily). On the contrary, other ARB trials (IDNT [Irbesartan Diabetic Nephropathy Trial], IRMA2 [Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria], RENAAL [Reduction of End points in NIDDM with the Angiotensin II Antagonist Losartan], and LIFE [Losartan Intervention for End Point Reduction in Hypertension]) have had such clear-cut outcomes that irbesartan (300mg) and losartan (100mg) are the drugs of choice in type 2 diabetes patients with proteinuria or in hypertensive patients with left ventricular hypertrophy. The key factor for ARBs to succeed in delivering superior organ protection appears to be the high dosages used, dosages uncommonly utilised, with some exceptions, to treat hypertension in clinical practice. The results of the published ARB trials are reviewed, focusing on the dose-efficacy of target-organ protection beyond blood pressure control.

ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS

摘要:

Hypertension and cardiovascular disease prevention is a vast and evolving area for researchers, primary care physicians and specialists. To help keep you up-to-date with the latest advances worldwide on all aspects of drug therapy and management in this area, this section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly1. The following reports are selected from the latest issues, summarising the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse reaction news, and expert opinion pieces published across a broad range of literature sources.

ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS

ISSN:1120-9879    

出版商:ADIS    

年代:2004

数据来源: ADIS